NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: ADAP Advocacy's 340B Drug Pricing Program Infographics on Executive Compensation
TL;DR
ADAP Advocacy's report reveals how hospital CEOs gain unfair financial advantages by diverting 340B program funds meant for patient care into excessive executive compensation packages.
ADAP Advocacy published infographics showing how the 340B Drug Pricing Program's $66 billion in manufacturer rebates are systematically redirected from patient services to fund hospital CEO compensation packages.
ADAP Advocacy's findings expose how excessive hospital CEO pay compromises the 340B program's mission to provide healthcare access for poor patients and vulnerable communities.
ADAP Advocacy's infographics reveal that hospital CEO compensation grew exponentially after hospitals became eligible for the 340B program originally designed to help poor patients.
Found this article helpful?
Share it with your network and spread the knowledge!
The infographics focus on excessive executive compensation packages among hospital CEOs and how manufacturer rebates from the 340B Drug Pricing Program are being used to fund these compensation packages rather than helping poor patients access healthcare services as intended.
The 340B Drug Pricing Program was designed to help poor patients access healthcare services by providing discounted drug prices to eligible healthcare providers serving vulnerable populations.
ADAP Advocacy is concerned because despite the program growing to $66 billion, manufacturer rebates are being used to fund excessive compensation for hospital CEOs rather than directly benefiting poor patients as originally intended.
Part 1 focuses on the CEO pay gap relative to frontline nurses and how 340B rebates fund excessive compensation. Part 2 shows how CEO pay has grown exponentially after hospitals became eligible to participate in the 340B Program.
ADAP Advocacy is an organization whose mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS through awareness, education, and community collaboration.
The two-part infographic series can be downloaded online at https://www.adapadvocacy.org/publications.html#i.
The '340B Too Big to Fail' campaign is ADAP Advocacy's national advocacy campaign questioning whether the 340B Drug Pricing Program has become so large and misused that it represents a 'too big to fail' scenario while not serving its intended purpose.
The infographics were published on November 25, 2025, as part of ADAP Advocacy's ongoing 340B Project.
Patients, healthcare advocates, community organizations, government officials, and anyone concerned about equitable healthcare access should be concerned, as the program intended to help poor patients is being diverted to fund excessive executive compensation.
You can email info@adapadvocacy.org to learn more about ADAP Advocacy, the 340B Drug Pricing Program, or the new '340B Too Big to Fail' infographics.
Curated from 24-7 Press Release
